References
- Fjällskog M-L, Lejonklou MH, Öberg K, Eriksson B, Janson ET. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003;9:1469–73.
- Granberg D, Wilander E, Öberg K. Expression of tyrosine kinase receptors in lung carcinoids. Tumor Biol 2006;27:153–7.
- Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, . The Israel Glivec in Solid Tumors Study Group. The role of Imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006;13:535–40.
- Yao JC, Zhang JX, Rashid A, Yeung S-CJ, Szklaruk J, Hess K, . Clinical and in vitro studies of imatinib in advanced carinoid tumors. Clin Cancer Res 2007;13:234–40.
- Mathy A, Baas P, Dalesio O, van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial. Lung Cancer 2005;50:83–6.
- Soria JC, Johnson BE, Chevalier TL. Imatinib in small cell lung cancer. Lung Cancer 2003;41(Suppl 1):S49–S53.
- Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, . Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma, significant toxicity with no clinical efficacy. Cancer 2006;106:2005–11.
- Vuky J, Isacsson C, Fotoohi M, Dela Cruz J, Otero H, Picozzi V, . Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. Invest New Drugs 2006;24:85–8.